Symbols

IIPR

Innovative·NYSE

--(--)

IIPR fundamentals

IIPR Q4 2025 Earnings

Innovative (IIPR) released its earnings on Feb 23, 2026: revenue was 66.66M (YoY -13.14%), beat estimates; EPS was 1.06 (YoY -22.06%), beat estimates.

Revenue / YoY

66.66M

-13.14%

EPS / YoY

1.06

-22.06%

Report date

Feb 23, 2026

IIPR Earnings Call Summary for Q4,2025

Cannabis Regulatory Breakthrough: Schedule III rescheduling could eliminate 280E tax penalty, +$3.7M in Q4 recoveries.
Portfolio Turnaround: 900K sq ft re-leasing pipeline, 26% of rent in high-growth states.
Life Science Diversification: $150M IQHQ investment, 25% pre-leasing, 6M sq ft pipeline decline.
Financial Strength: $107M liquidity, 10x debt coverage, $40M preferred stock issuance at 9.5%.
Tenant Recovery: 4Front/PharmaCann re-leasing at $10-15/sq ft, $7M judgment collection.

Earnings

EPS

Revenue

Revenue & Expenses

IIPR has released its 2025 Q4 earnings report, with revenue of 66.66M, reflecting a YoY change of -13.14%, and net profit of 31.84M, showing a YoY change of -20.45%. The Sankey diagram below clearly presents IIPR's revenue sources and cost distribution.

Key Indicators

Innovative (IIPR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Innovative (IIPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Innovative (IIPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Innovative (IIPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown